Calendario›AMGN›Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Ensayo de AMGEN INC en Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) · Thrombocytopenic Purpura (del registro, en inglés).

Fase

no aplica

Estado

Completado

Participantes

326

previstos

Fin del objetivo primario

jun 2008

fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en may 2006.

Qué mide

Number of Participants Utilizing Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Therapies for First-line Treatment (Includes the retrospective chart review (from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever was less) and the prospective portion of the study (enrollment through Month 12).) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a multi-center prospective observational descriptive study complemented by a retrospective chart review. Patients diagnosed with ITP and currently treated for ITP by a hematologist or hematologist-oncologist will be recruited from community-based clinics and academic/referral centers. They will be followed prospectively for a period of 12 months. At inception, participants' charts will also be reviewed from the date of enrollment retrospectively to the date of diagnosis or the previous 36 months, whichever is less.

Más ensayos de AMGN

Todos los de AMGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00454857), actualizada en oct 2013.